All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation

The Multiple Myeloma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Why daratumumab + VRd + cyclophosphamide might be an option to consider for high-risk NDMM?

During the 2021 ASCO Annual Meeting and the EHA2021 Virtual Congress, the Multiple Myeloma Hub spoke with Martin Kaiser, The Institute of Cancer Research, London, UK. We asked, Why daratumumab + VRd + cyclophosphamide might be an option to consider for high-risk newly diagnosed multiple myeloma (NDMM)?

In this video, Kaiser discusses a potentially improved treatment regimen for high-risk and ultra high-risk patients with NDMM being evaluated in the OPTIMUM/MUKnine trial (NCT03188172).


Share: